WallStreetZenWallStreetZen

NASDAQ: TRAW
Traws Pharma Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their TRAW stock forecasts and price targets.

Forecast return on equity

Is TRAW forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36%

Forecast return on assets

Is TRAW forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

TRAW revenue forecast

What is TRAW's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$5.5M+2,333.63%
Avg 2 year Forecast
$300.0k+32.74%
Avg 3 year Forecast
$300.0k+32.74%

TRAW vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRAW$0.67N/AN/A
EDSA$4.45$21.00+371.91%Buy
SNTI$0.31N/AN/A
PIRS$0.15N/AN/A
TNXP$0.16$3.00+1,775.00%Strong Buy

Traws Pharma Stock Forecast FAQ

What is TRAW's revenue growth forecast for 2024-2026?

(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Traws Pharma's revenue in 2024 is $226,000.On average, 1 Wall Street analysts forecast TRAW's revenue for 2024 to be $115,723,548, with the lowest TRAW revenue forecast at $115,723,548, and the highest TRAW revenue forecast at $115,723,548. On average, 1 Wall Street analysts forecast TRAW's revenue for 2025 to be $6,312,194, with the lowest TRAW revenue forecast at $6,312,194, and the highest TRAW revenue forecast at $6,312,194.

In 2026, TRAW is forecast to generate $6,312,194 in revenue, with the lowest revenue forecast at $6,312,194 and the highest revenue forecast at $6,312,194.

If you're new to stock investing, here's how to buy Traws Pharma stock.

What is TRAW's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: TRAW) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is TRAW's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: TRAW) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.